BOLT vs T · rev $7.7M vs P/E 7.4, rev $125.65B
Bolt Biotherapeutics (BOLT) versus AT&T Inc. (T) — a side-by-side from cached financials, not a winner call.
Bolt Biotherapeutics (BOLT) is a biotechnology company listed on US.
AT&T Inc. (T) is a telecom services company listed on NYSE. It is led by John Stankey.
Latest reported BOLT revenue for 2024-12-31 was $7.7M. Net income was -$63.1M. Revenue was down 2.4% from 2023-12-31 to 2024-12-31. BOLT currently screens at market cap $11.3M.
Latest reported T revenue for 2025-12-31 was $125.65B. Net income was $21.95B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. T currently screens at market cap $155.92B and trailing P/E 7.4.
BOLT currently screens at market cap $11.3M. T currently screens at market cap $155.92B and trailing P/E 7.4.
Not investment advice. Open the BOLT and T stock pages for the full models.
Not investment advice.